News | October 09, 2025
Briefs: Panacea Biotec and Shukra Pharmaceuticals
Panacea Biotec receives acceptance from CMSS for supply of bOPV
Panacea Biotec receives acceptance from CMSS for supply of bOPV
Encouraging early detection and breaking the silence around men’s health
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
AINU is set to accelerate its expansion footprint, enhance operational capabilities
New platform powered by Opentrons expands lab automation to accelerate scientific discovery
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
Subscribe To Our Newsletter & Stay Updated
